Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04582669 · ClinicalTrials.gov registry record · Phase 4
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
A Phase 4 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT04582669: Clinical Trial Phase 4 study, sponsored by Montefiore Medical Center.
NCT04582669 is a Phase 4 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04582669, a Phase 4 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses. The goal of this study is to determine the efficacy of treating HS flares with ILTAC-10, ILTAC-20 and ILTAC-40 and to investigate the side effect profile for each dose.
Primary Outcome
Numeric Rating Scale is a pain scale scored with whole integers from 0 to 10, with 0 being "no pain" and 10 being "the worst pain imaginable". Higher score indicates worse pain.
Interventions
- DRUG Placebo
- DRUG Intralesional Triamcinolone 10 mg/mL
- DRUG Intralesional Triamcinolone 20 mg/mL
- DRUG Intralesional Triamcinolone 40 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2022-10-12 |
| Phase | Phase 4 |
Why NCT04582669 stopped before completion
NCT04582669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04582669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04582669 about?
NCT04582669 is a clinical study titled "Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa". Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses. The goal of this study is to determine the efficacy of treating HS flares with ILTAC-10, ILTAC-20 ...
What is the current status of trial NCT04582669?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2022-01-24. Estimated completion is 2022-10-12.
What interventions are being tested in trial NCT04582669?
The interventions under investigation include: Placebo (DRUG), Intralesional Triamcinolone 10 mg/mL (DRUG), Intralesional Triamcinolone 20 mg/mL (DRUG), Intralesional Triamcinolone 40 mg/mL (DRUG).
Who is sponsoring clinical trial NCT04582669?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04582669's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI